Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine Maintenance in Diabetic Peripheral Neuropathic Pain
NCT00322621Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, open-label, single-arm trial of duloxetine in diabetic polyneuropathy (DPN), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline (Week 8) in Brief Pain Inventory (BPI) 24-hour Average Pain Item Score at Week 34. Started Apr 2006; status: completed.
02
Drugs
duloxetine
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT00322621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322621.